Pinkal Desai, MD
Hematology & Oncology · New York, NYNPI 1952539546
Payments from drug & device makers
Across 158 payments — averaging $19,350 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$1.4M
- Acerta Pharma LLC$849K
- AstraZeneca$274K
- Novartis$197K
- Janssen Research & Development, LLC$122K
- E.r. Squibb & Sons, L.L.C.$77K
- plus $186K from 18 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 22 | $1,351,889 |
| Acerta Pharma LLC | 2 | $848,725 |
| AstraZeneca(2 entities) | 7 | $273,899 |
| Novartis | 15 | $197,484 |
| Janssen Research & Development, LLC | 15 | $121,747 |
| E.r. Squibb & Sons, L.L.C. | 19 | $77,093 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $72,679 |
| Astellas Pharma Global Development | 3 | $36,800 |
| Bristol Myers Squibb | 27 | $24,903 |
| Otsuka Pharmaceutical Co., Ltd. | 1 | $19,950 |
| Taiho Oncology, Inc. | 1 | $13,300 |
| Amgen | 2 | $11,030 |
| Gilead | 3 | $2,350 |
| Astellas Pharma US Inc | 6 | $1,722 |
| AbbVie | 5 | $1,642 |
| Agios Pharmaceuticals, Inc. | 1 | $1,000 |
| Genentech USA, Inc. | 3 | $290 |
| Rigel Pharmaceuticals, Inc. | 2 | $207 |
| Geron Corporation | 5 | $158 |
| Janssen Scientific Affairs, LLC | 1 | $142 |
| Astrazeneca UK Limited | 2 | $135 |
| Jazz Pharmaceuticals Inc. | 1 | $100 |
| Pfizer | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
How this compares
$3,057,285 in reported general payments places this provider in the 90th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in New York
- Vicky MakkerNew York$27.1M
- Alison MoskowitzNew York$22.7M
- Ajai ChariNew York$22.4M
- Yelena JanjigianNew York$16.9M
- Alexander LesokhinNew York$11.9M
- John MascarenhasNew York$11.8M
- Maria PalombaNew York$11.6M
- Scott TagawaNew York$10.3M
- Mohammad Abdul HayNew York$9.9M
- Joshua SabariNew York$9.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.